Objectives
Evaluate real-world progression-free survival
Data controller
Intergroupe Francophone de Cancérologie Thoracique (IFCT)
Categories of data used
Données d’identification (sans donnée nominative) / Données de santé
Origine de données utilisées
Soins
Institut de Cancérologie de l'Ouest (Nantes et Angers)
Population subject to research or data processing
Patients with Stage IV NSCLC at time of initiation of treatment with sotorasib • Presence of KRAS G12C mutation diagnosed on tumor sample and/or on liquid biopsy (co mutations allowed) • Patients who received at least one dose of the treatment with sotorasib as part of the French Early Access Program (ATU program) • Patients who were informed about the study and do not object for their data to be collected • Age > 18 years
Legal basis
Intérêt public
Internal and external data recipients
IFCT
Research start date
24/03/2022
Data retention period
Durée conforme à la réglementation